Previous 10 | Next 10 |
2023-08-24 09:19:41 ET Summary X4 is nearing approval of its lead candidate for WHIM syndrome and aims for label expansion to a much larger market of chronic neutropenias. Despite very small WHIM target population, orphan designation (=premium pricing) and potential for non-diluti...
2023-08-10 13:25:55 ET Gainers: WeWork ( WE ) +87% . Capri Holdings Limited ( CPRI ) +56% . Black Spade Acquisition ( BSAQ ) +58% . Edible Garden AG Incorporated ( EDBL ) +43% . Lion Group Holding Ltd. ( LGHL ) +37% . Precige...
2023-08-10 12:38:10 ET X4 Pharmaceuticals, Inc. (XFOR) Q2 2023 Results Conference Call August 10, 2023 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Paula Ragan - CEO Adam Mostafa - CFO Murray Stewart - Interim CMO Mark Baldry - CCO C...
2023-08-10 10:27:32 ET Gainers: LifeMD ( LFMD ) +20% . Precigen ( PGEN ) +19% . Repare Therapeutics ( RPTX ) +16% . Cosmos Health ( COSM ) +13% . GoodRx Holdings ( GDRX ) +13% . Losers: Galera Therapeutics ( GRTX ) -...
2023-08-10 08:25:22 ET Galera Therapeutics ( GRTX ) -82% . Origin Materials ( ORGN ) -57% after Q2 earning release . Organogenesis Holdings ( ORGO ) -32% after Q2 earning release . Renovaro Biosciences ( RENB ) -23% . Wolverine World...
2023-08-10 06:08:02 ET X4 Pharmaceuticals press release ( NASDAQ: XFOR ): Q2 GAAP EPS of -$0.33 misses by $0.16 . X4 had $142.3 million in cash, cash equivalents, restricted cash, and marketable securities as of June 30, 2023. For further details see: X4 Phar...
Submission of first U.S. New Drug Application for mavorixafor in WHIM syndrome on track for early 2H 2023 Emerging data from ongoing Phase 2 trial in certain chronic neutropenic disorders show mavorixafor durably increased neutrophil counts and enabled reductions in G-CSF dosing ...
BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that Christophe Arbet-Engels, MD, PhD, will be joining ...
BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today announced the closing of a $115 million loan facility with Hercules ...
BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the sec...
News, Short Squeeze, Breakout and More Instantly...
X4 Pharmaceuticals Inc. Company Name:
XFOR Stock Symbol:
NYSE Market:
X4 Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 30.9% to $0.6 on volume of 558,931,853 shares NVIDIA Corporation (NVDA) fell 1.9% to $123.99 on volume of 249,243,816 shares Assure Holdings Corp. (IONM) rose 82.8% to $0.424 on vol...
100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increase with once-daily, oral mavorixafor +/- stable-dose G-CSF as of the interim analysis data cut-off date Durable mean ANC levels above the lower limit of normal for CN were achieved for partic...
BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will host a virtual investor event on Thursday, June 27, 2024 at 8:00 am ET. To register for the eve...